Skip to main content

Table 5 Bacterial pathogens isolated on days 0 and 7 from lower respiratory tract lesions, bronchoalveolar lavage and nasal swabs, minimum inhibitory concentrations (MIC) and susceptibilities to marbofloxacin and enrofloxacin

From: Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

   Marbofloxacin Enrofloxacin
MIC range MIC50 MIC90 S% n MIC range MIC50 MIC90 S% n
A. pleuropneumoniae Day 0 0.03–0.12 0.06 0.06 100 61 0.015–0.12 0.06 0.06 100 61
Day 7 nc nc nc nc 0 nc nc nc nc 0
H. parasuis Day 0 0.25–2.0 0.015 0.06 n/a 18 0.004–1.0 0.015 0.03 n/a 13
Day 7 0.015 nc nc n/a 2 0.008 nc nc n/a 2
P. multocida Day 0 0.008–0.03 0.015 0.03 100 32 0.004–0.015 0.008 0.015 100 32
Day 7 0.008–0.03 0.015 0.03 100 18 0.008–0.015 0.008 0.008 100 18
B. bronchiseptica Day 0 0.25–1.0 0.5 0.5 n/a 92 0.25–0.5 0.5 0.5 n/a 92
Day 7 0.25–0.5 0.5 0.5 n/a 138 0.25–1.0 0.5 0.5 n/a 134
  1. MIC50, MIC90, lowest concentrations (μg/mL) of the antimicrobial for which 50 and 90% of the isolates were inhibited, respectively; n, total number of isolates from lung/lower respiratory tract, bronchoalveolar lavage and nasal swabs, combined, for which MIC was determined; n/a susceptibility data not available; nc, not calculated for <10 isolates; S, percentage of isolates within a species that were susceptible to the antimicrobial based on European susceptibility monitoring and where available CLSI breakpoints [28, 29, 38]